Results 61 to 70 of about 286,222 (357)

HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques

open access: yesNature Communications
Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal ...
Massimiliano Bissa   +24 more
doaj   +1 more source

Biomaterial-enhanced cancer vaccines

open access: yesMaterials & Design, 2022
Cancer vaccines are a promising strategy for preventing cancer progression through antitumor immunity activation. Some vaccines, such as Sipuleucel-T (an autologous active cellular immunotherapy), have been applied clinically.
Shengxian Li   +4 more
doaj   +1 more source

Cancer vaccines

open access: yesBMJ, 2015
Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a ...
openaire   +3 more sources

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models

open access: yesAdvanced Functional Materials, EarlyView.
Structure–activity relationship (SAR) optimization of bio‐reducible ionizable lipids enables the development of highly effective lipid nanoparticle (LNP) mRNA vaccines. Lead LNPs show superior tolerability and antibody responses in rodents and primates, outperforming approved COVID‐19 vaccine lipids.
Ruben De Coen   +30 more
wiley   +1 more source

Potential association factors for developing effective peptide-based cancer vaccines

open access: yesFrontiers in Immunology, 2022
Peptide-based cancer vaccines have been shown to boost immune systems to kill tumor cells in cancer patients. However, designing an effective T cell epitope peptide-based cancer vaccine still remains a challenge and is a major hurdle for the application ...
Chongming Jiang   +14 more
doaj   +1 more source

Biological therapy in the treatment of melanoma [PDF]

open access: yes, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile   +8 more
core   +3 more sources

Prostate cancer vaccines

open access: yesExpert Review of Vaccines, 2013
In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that ...
Michael, Agnieszka   +3 more
openaire   +5 more sources

Ice Lithography: Recent Progress Opens a New Frontier of Opportunities

open access: yesAdvanced Functional Materials, EarlyView.
This review focuses on recent advancements in ice lithography, including breakthroughs in compatible precursors and substrates, processes and applications, hardware, and digital methods. Moreover, it offers a roadmap to uncover innovation opportunities for ice lithography in fields such as biological, nanoengineering and microsystems, biophysics and ...
Bingdong Chang   +9 more
wiley   +1 more source

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

open access: yesFrontiers in Pharmacology, 2021
Cancer vaccines represent among the most promising strategies in the battle against cancers. However, the clinical efficacy of current cancer vaccines is largely limited by the lack of optimized delivery systems to generate strong and persistent ...
Lu Han   +6 more
doaj   +1 more source

Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation [PDF]

open access: yes, 2019
Human cytomegalovirus (HCMV) induces a uniquely high frequency of virus-specific effector/memory CD8+ T-cells, a phenomenon termed “memory inflation”.
Abate   +109 more
core   +1 more source

Home - About - Disclaimer - Privacy